- Our Doctors
- Dr Kathleen Batty
Dr Kathleen Batty
BMed/MD FRACP, Medical Oncologist
Languages spoken
English
Overview
Centres
Clinical interests
Clinical interest in breast, gynecological and genitourinary cancers, supportive care and lifestyle medicine.
Dr Kathleen Batty is a Medical Oncologist who works at Northern Beaches Hospital and Genesis Care Frenchs Forest. She completed her oncology training at Royal North Shore Hospital where she was the Oncology Clinical Trials Fellow in 2021. She undertook further training as the Cunningham Fellow in Breast Cancer at the Kinghorn Cancer Centre in 2022 where she was the recipient of the Beverley Alt Educational Scholarship. Her main areas of interest are breast, gynaecological, and gastrointestinal cancers with further interests in survivorship and the psychosocial issues faced by patients with cancer. She is a keen runner and believes that exercise and lifestyle optimisation are a vital part of cancer treatment for all patients.
Professional memberships
- Royal Australian College of Physicians
- Breast Cancer Trials Group
- Medical Oncology Group of Australia
Publications
- Batty K, Taylor AM, Bernard EJ, Diakos CI, Clarke SJ, Guminski A, Baron-Hay S, Boyle F, Pavlakis N, Chan DL. Metastatic primary breast neuroendocrine neoplasms: a case series. Internal Medicine Journal. 2022. https://doi.org/10.1111/imj.15961
- Bhave P, Ahmed T, Lo S, Shoushtari A, Zaremba A, Versluis J, Mangana J, Weichenthal M, Si L, Lesimple T, Robert C, Trojanelly C, Wicky A, Heywood R, Tran L, Batty K et al. Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma. Journal for Immuno Therapy of Cancer. 2022; 10:e004668. doi: 10.1136/jitc-2022-004668
- Batty K, Li M, Baron-Hay S. Pembrolizumab as adjuvant therapy in a patient with Lynch syndrome with synchronous mixed clear cell carcinoma of ovarian origin and endometroid endometrial carcinoma. BMJ Case Rep. 2021 Nov 12;14(11)
- Atkinson V, Batty K, Long GV, Carlino MS, Peters GD, Bhave P, Moore MA, Xu W, Brown LJ, Arneil M, Lyle M, and Menzies AM. Activity and safety of third-line BRAF-targeted therapy (TT) following first-line TT and second-line immunotherapy (IT) in advanced melanoma. Journal of Clinical Oncology. 2020 38:15_suppl, 10049-10049
- Wang X, Batty KM, Crowe PJ, Goldstein D and Yang J-L. The potential of pan-HER inhibition in cancer. Frontiers in Oncology. 2015; 5:2. doi: 10.3389/fonc.2015.00002
Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.